

ACNP

AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY

57th

ANNUAL MEETING

GENERAL
INFORMATION

HOLLYWOOD, FLORIDA
THE DIPLOMAT BEACH RESORT

DECEMBER 9-13, 2018

Disclosures for 2018 speakers (mini-panels, panel, study group, and plenary) and poster presenters may be found online at: <https://acnp.org/> (click the Annual Meeting tab)

TABLE OF CONTENTS

Acknowledgments	Page 3
ACNP Council	Page 4
Program Committee	Page 4
In Memoriam	Page 5
General Information	Page 6
Dates and Location	Page 6
Annual Meeting Schedule	Page 6
Executive Office Information	Page 6
Code of Conduct	Page 6
Americans with Disabilities Act	Page 7
Program Overview	Page 7
Statement of Need	Page 7
Target Audience	Page 8
Learning Objectives	Page 8
Meeting Evaluation	Page 8
Continuing Medical Education (CME)	Page 8
Disclosures	Page 9-13

Acknowledgements

The American College of Neuropsychopharmacology appreciates the support of our supporting corporations:

ACADIA Pharmaceuticals Inc.
Alkermes, Inc.
Allergan, PLC
Astellas Pharma
Avanir Pharmaceuticals
EiSai Inc.
H. Lundbeck A/S, Denmark
Hoffman-LaRoche, Inc.
Intra-Cellular Therapies, Inc.
Janssen Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Otsuka Pharmaceutical Development and Commercialization, Inc.
Sage Therapeutics
Sunovion Pharmaceuticals, Inc.
Takeda Pharmaceuticals

The American College of Neuropsychopharmacology express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

Alkermes, Inc.
Janssen Research & Development, LLC (Travel Award Program Sponsor)
Neurocrine Biosciences, Inc.
Sunovion Pharmaceuticals, Inc.

ACNP Council

Officers and Council

<i>President</i>	Steven Hyman
<i>President-Elect</i>	Marina Wolf
<i>President-Elect Designate</i>	Maria Oquendo
<i>Past President (18-19)</i>	Anissa Abi-Dargham
<i>Past President (17-18)</i>	Alan Frazer
<i>Secretary</i>	Joseph Coyle
<i>Treasurer</i>	David J. Kupfer

<i>Council</i>	Victoria Arango Antonello Bonci Judith Ford Bitá Moghaddam Kerry Ressler Rita Valentino
----------------	--

<i>Council-Elect</i>	Helen Mayberg Trevor Robbins
----------------------	---------------------------------

Program Committee

2018 Program and Scientific Communications Committee

<i>Chair</i>	Linda Brady
<i>Co-Chair</i>	Susan Amara
<i>Council Liaison</i>	Steve Hyman

Members:

Susanne Ahmari	Guillermo Horga	Thomas Schlaepfer
Sabina Berretta	Amir Kalali	Yavin Shaham
Charles Bradberry	John Krystal	Alicia Smith
Jose Canive	Thomas Lehner	Vikaas Sohal
Cameron Carter	Julio Licinio	Stephen Strakowski
Joseph Cheer	Fang Liu	Susan Swedo
Christoph Correll	Lin Mei	Sophia Vinogradov
Kathryn Cullen	Kathleen Merikangas	Aristotle Voineskos
Katharina Domschke	Eric Morrow	Claes Wahlestedt
Stephanie Dulawa	Andrew Nierenberg	Mark Weiser
Thomas Fernandez	Patricio O'Donnell	
Howard Gendelman	Abraham Palmer	
Birte Glenthøj	Douglas Ruderfer	
Anthony Grace	Theodore Satterthwaite	

In Memoriam

Randal Ross
December 20, 2016

Ronald Fieve
January 2, 2018

Arvid Carlsson
June 29, 2018

David Jacobowitz
September 7, 2018

Bernard Carroll
September 10, 2018

Herbert Kleber
October 5, 2018

Naomi Breslau
October 13, 2018

General Information

Dates and Location

Dates: Sunday, December 9, 2018 - Thursday, December 13, 2018
Location: The Diplomat Beach Resort

Future ACNP Annual Meetings

<u>Dates</u>	<u>Hotel</u>	<u>Location</u>
December 8 - 11, 2019	Hilton Orlando Bonnet Creek	Orlando, Florida
December 6 - 9, 2020	JW Marriott Desert Ridge Resort	Phoenix, Arizona
December 5 - 8, 2021	San Juan Convention Center	San Juan, Puerto Rico
December 4 - 7, 2022	JW Marriott Desert Ridge Resort	Phoenix, Arizona

Annual Meeting Schedule

All scientific registrants can access the Annual Meeting Schedule for the 57th ACNP Annual Meeting at: <https://acnp.societyconference.com/conf/#sessions/conf10027>

ACNP Executive Office

ACNP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027
USA

Phone: 615-324-2360
Fax: 615-523-1715
E-mail: acnp@acnp.org

Code of Conduct

The American College of Neuropsychopharmacology is dedicated to providing a safe and productive experience for all participants and attendees at all official ACNP events regardless of sex, race, color, national origin, religion, age, physical or mental disability, perceived disability, ancestry, marital status, sexual orientation, or any other basis protected by federal or pertinent state laws. ACNP does not tolerate discrimination or any form of prohibited harassment and is committed to enforcing this Code of Conduct (the “Code”) at its Annual Meeting or at any other ACNP event. Please [click here](#) for full Code of Conduct.

Americans with Disabilities Act

It is the policy of the American College of Neuropsychopharmacology not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-324-2360 or send an email to acnp@acnp.org.

Program Overview

Statement of Need

The field of Neuropsychopharmacology is in need of taking the wealth of available clinical and preclinical data to improve the quality of research and clinical practice. There are clear unmet needs for psychiatric disorders, yet the field has been slow in delivering novel therapeutics (Hyman, 2014; Bernal et al., 2016). There is a need for translating findings from genome-wide association studies for psychiatric disorders into new targets for therapeutics discovery (Breen, 2016). There is an acute need for biomarkers that can be used for diagnosing and subtyping patients or predicting treatment outcomes with neurodegenerative disease and psychiatric disorders (e.g., neuroimaging, electrophysiological and inflammatory markers in blood and/or CSF). There are new quantitative biological approaches for understanding and classifying neuropsychiatric disorders (Kas et al., 2017) and emerging digital technologies (mobile, computer, and device-based cognitive tools) that can be used as objective measurements in clinical trials (Krishna, 2017). Best practices for research and clinical work can benefit from the dissemination of emerging information, and this is an age in which the fields of basic and clinical neuroscience are providing an enormous amount of novel information. Integrating such data onto researchers and clinicians' activities will allow the field to move forward, getting us closer to needed breakthroughs. This type of progress is what we need for industry to eventually deliver novel psychiatric medications (O'Donnell and Ehlers, 2015) and breakthrough therapy designations.

REFERENCES

- Bernal A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, Millan MJ, Bastlund JF, Doller D, Witkin J, Moser P, O'Donnell P, Ebert U, Geyer MA, Prinszen E, Ballard T, Macleod M (2016) Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. *Nat Rev Drug Discov* 15:516.
- Breen G, [Li Q](#), [Roth BL](#), [O'Donnell P](#), [Didriksen M](#), [Dolmetsch R](#), [O'Reilly PF](#), [Gaspar HA](#)¹, [Manji H](#), [Huebel C](#), [Kelsoe JR](#), [Malhotra D](#), [Bertolino A](#), [Posthuma D](#), [Sklar P](#), [Kapur S](#), [Sullivan PF](#), [Collier DA](#), [Edenberg HJ](#). Translating genome-wide association findings into new therapeutics for psychiatry. *Nat Neurosci*. 2016 Oct 26;19(11):1392-1396. doi: 10.1038/nn.4411.
- Kas MJ, [Penninx B](#), [Sommer B](#), [Serretti A](#), [Arango C](#), [Marston H](#) ((2017) A quantitative approach to neuropsychiatry: The why and the how. *Neurosci Biobehav Rev*. 2017 Dec 12. pii: S0149-7634(17)30534-1. doi: 10.1016/j.neubiorev.2017.12.008. [Epub ahead of print]
- Krishna R (2017) The emerging role of digital technologies in early clinical development. *Clin Pharmacology and Therapeutics* <https://doi.org/10.1002/cpt.906>

Hyman SE (2014) Revitalizing psychiatric therapeutics. *Neuropsychopharmacology* 39:220-229.

O'Donnell P, Ehlers MD (2015) Opportunities for New Drug Development in Psychiatry: A Glass Half-Full. *JAMA Psychiatry* 72:1067-1068.

Target Audience

The target audience includes members of the American College of Neuropsychopharmacology and invited experts. The audience includes physicians, psychologists, and basic neuroscientists from across the globe. The physicians include a number of specialties, with psychiatrists representing the majority of attendees, and neurologists next most common. Psychologists include clinical psychologists and neuropsychologists.

Learning Objectives

After participating in this CME activity, participants should be able to describe and discuss:

1. How the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area impact your current or potential future research projects.
2. How you will change or modify a current approach or strategy in your current or potential future research projects based on what you learned from the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area.
3. How recent progress in identifying genetic variations that are risk factors for the development of psychiatric disorders affect your current or potential future research projects.

Meeting Evaluation

All meeting attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation in the ACNP Computer Center located in the Grand Ballroom Foyer or on-line at <https://acnp.org/> (click the Annual Meeting tab). All evaluations must be completed by January 14, 2019.

Continuing Medical Education and Disclosures

Attendees will be eligible to receive the credit hours listed below for attending the full 57th Annual Meeting, December 9 - 13, 2018. The credit hour totals below include attending all available session times Sunday, December 9 - Thursday, December 13, 2018. To obtain CME credits for the conference, you must complete the post-conference meeting evaluation.

There will be a \$40.00 charge for scientific registrants to obtain CME credits. CME instructions will be available on the ACNP website (<https://acnp.org/>). Upon completion of the post-conference evaluation and attestation, your CME certificate will be emailed after January 14, 2019.

Physicians

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and the American College of Neuropsychopharmacology (ACNP). Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Amedco designates this live activity for a maximum of 34.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Relevant Financial Relationships with Commercial Interests

In order to meet ACCME requirements, Amedco requires [disclosure](#) of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. A copy of the disclosures can be found on the mobile app and online at <https://acnp.org/>.

Financial Relationships

Definition of Financial Relationship...

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers' bureau, ownership interest (e.g. stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considered relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Contracted research includes research funding where the institution gets the grant and manages the fund and the person is the principal or named investigator on the grant.

There is no minimum dollar amount for relationships.

Definition of Commercial Interest...

A *commercial interest* is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Providers of clinical service directly to patients are not commercial interests – unless the provider of clinical service is owned, or controlled, by a commercial interest. The following are not commercial interests:

- 501-C Non-profit organizations that do not advocate for commercial interests
- Government organizations
- Non-health care related companies
- Liability insurance providers
- Health insurance providers

- Group medical practices
- For-profit hospitals
- For-profit rehabilitation centers
- For-profit nursing homes
- Blood banks
- Diagnostic laboratories

Relevant financial relationships exist between the following individuals and commercial interests:

2018 Council Disclosures

Abi-Dargham, Anissa:

Neurocrine: Grant (Self) Otsuka: Honoraria (Self) Roche: Advisory Board (Self) System1 Biosciences, Inc: Stock/Equity (Self)

Bonci, Antonello:

Gallimberti Bonci & Partners: Consultant (Self)

Ford, Judith:

Alkermes: Consultant (Spouse) Boehringer-Ingelheim: Consultant (Spouse)

Frazer, Alan:

Alkermes: Advisory Board (Self) Oxford University Press: Honoraria (Self)

Hyman, Steven:

BlackThorn: Consultant (Self) Fprime: Consultant (Self) Janssen: Consultant (Self) Q-State Biosciences: Board Member (Self) Voyager Therapeutics: Board Member (Self)

Kupfer, David:

HealthRhythms, Inc.: Board Member (Spouse) HealthRythems, Inc.: Stock/Equity (Self) Minerva Neuroscience: Board Member (Self) Pittsburgh Sleep Quality Index (PSQI): Royalties (Self) Psychiatric Assessments, Inc.: Consultant (Self and Spouse) Servier, Inc.: Consultant (Self and Spouse)

Mayberg, Helen:

Abbott (previously St Jude Medical, Inc.): Patent (Self)

Oquendo, Maria:

Research Foundation for Mental Hygiene: Royalties (Self) Bristol Myers Squibb: Stock/Equity (Spouse)

Ressler, Kerry:

Biogen: Consultant (Self) Resilience Therapeutics: Advisory Board (Self)

Robbins, Trevor:

Cambridge Cognition: Consultant (Self and Spouse) Cambridge Cognition: Royalties (Self and Spouse) Elsevier: Honoraria (Self) Mundipharma: Consultant (Self and Spouse) Shionogi: Grant (Self) SmallPharma: Grant (Self) Springer Verlag: Honoraria (Self) Unilever: Advisory Board (Self)

Wolf, Marina:

CIS Biotech: Stock/Equity (Self) Grace Laboratories: Stock/Equity (Self)

Council members with nothing to disclose:

Arango, Victoria
Coyle, Joseph
Moghaddam, Bitu
Valentino, Rita

2018 Program Committee Disclosures

Correll, Christoph:

Alkermes: Consultant (Self) Allergan: Consultant (Self) Angelini: Consultant (Self)
IntraCellular Therapies: Consultant (Self) Janssen: Consultant (Self) LB Pharma:
Consultant (Self) Lundbeck: Consultant (Self) Neurocrine: Consultant (Self) Otsuka:
Consultant (Self) Pfizer: Consultant (Self) ROVI: Consultant (Self) Sunovion: Consultant
(Self) Takeda: Consultant (Self) Teva: Consultant (Self) Servier: Consultant (Self)
Merck: Consultant (Self)

Fernandez, Thomas:

Cogstate: Consultant (Self) Aevi Genomic Medicine: Consultant (Self) NIH: Grant (Self)
Brain & Behavior Research Foundation: Grant (Self) Guidepoint: Consultant (Self)

Glenthøj, Birte:

I am leader of a Lundbeck Foundation Center of Excellence for Clinical Intervention and neuropsychiatric Schizophrenia Research (CINS) which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them.: Grant (Self) I am PI on a grant from H- Lundbeck A/S given to and managed by the institution: Grant (Self)

Grace, Anthony:

Takeda: Advisory Board (Self) Heptares: Consultant (Self) Boehringer-Ingelheim:
Consultant (Self)

Kalali, Amir:

Bracket: Consultant (Self) Aicure: Consultant (Self) BlackThorn: Consultant (Self)
Platypus Institute: Consultant (Self)

Krystal, John:

Janssen: Patent (Self) Biohaven Pharmaceuticals: Stock / Equity (Self) ArRett Bioscience: Stock / Equity (Self) Takeda Pharma: Consultant (Self) Sunovion: Consultant (Self) AstraZeneca Pharmaceuticals: Consultant (Self) Biogen, Idec, MA: Consultant (Self) Biomedisyn Corporation: Consultant (Self) Bionomics, Limited: Consultant (Self) Heptares Therapeutics, Limited: Consultant (Self) Janssen Research & Development: Consultant (Self) L.E.K. Consulting: Consultant (Self) Otsuka America Pharmaceutical, Inc.: Consultant (Self) Pragma Therapeutics: Consultant (Self) S K Life Science: Consultant (Self) Spring Care, Inc.: Consultant (Self) Taisho Pharmaceutical Co., Ltd.: Consultant (Self) Teva Pharmaceutical R&D: Consultant (Self) Bioasis Technoligices, Inc.: Advisory Board (Self) Biohaven Pharmaceuticals: Advisory Board (Self) Blackthorn Therapeutics, Inc.: Advisory Board (Self) Broad Institute at MIT and Harvard: Advisory Board (Self) Lohocla Research Corporations: Advisory Board (Self) Prizer Pharmaceuticals: Advisory Board (Self) TRImaran Pharma: Advisory Board (Self) Blackthorn Therapeutics, Inc.: Stock / Equity (Self) Spring Health: Stock / Equity (Self) Biohaven Pharmaceuticals Medical Sciences: Stock / Equity (Self) Biological Psychiatry - Editor: Honoraria (Self)

Nierenberg, Andrew:

J and J: Grant (Self) Assurex: Advisory Board (Self) Assurex: Grant (Self) Otsuka: Advisory Board (Self) Alkermes: Advisory Board (Self) Neurocrine: Advisory Board (Self) NeuroRx: Grant (Self) Shire: Advisory Board (Self) Takeda: Grant (Self)

O'Donnell, Patricio:

Takeda: Employee (Self)

Sohal, Vikaas:

Neurona Therapeutics: Grant (Self)

Strakowski, Stephen:

Sunovion: Consultant (Self) Janssen: Grant (Self) Otsuka: Grant (Self)

Vinogradov, Sophia:

Research Consultant: Advisory Board (Self) Mindstrong, Inc.: Advisory Board (Self) Alkermes, Inc.: Advisory Board (Self)

Program Committee members with nothing to disclose:

Ahmari, Susanne
Amara, Susan
Berretta, Sabina
Bradberry, Charles
Brady, Linda
Canive, Jose
Carter, Cameron
Cheer, Joseph
Cullen, Kathryn
Domschke, Katharina

Dulawa, Stephanie
Gendelman, Howard
Horga, Guillermo
Lehner, Thomas
Licinio, Julio
Liu, Fang
Mei, Lin
Merikangas, Kathleen
Morrow, Eric
Palmer, Abraham

Ruderfer, Douglas
Satterthwaite, Theodore
Schlaepfer, Thomas
Shaham, Yavin
Smith, Alicia
Swedo, Susan
Voineskos, Aristotle
Wahlestedt, Claes
Weiser, Mark

2018 Staff Members Disclosures

Staff members with nothing to disclose:

Julie Cauthen
Erin Colladay
Evan Dickert
Lori Kunath
Julie Magill
Kelly Phy
Erin Shaw
Tori Swinehart
Sarah Timm